Deal Details

Sarepta Completes $575 Million Follow-On Offering

Healthcare

Sarepta follow-on offering

Summary

Sarepta Therapeutics, Inc. (“Sarepta” or the “Company”) (NASDAQ-GS:SRPT) recently completed an underwritten public offering of 7,098,766 shares of its common stock at a public offering price per share of $81.00. The offering included the full exercise by the underwriters of their option to purchase an additional 925,926 shares of common stock at the public offering price per share. The gross proceeds to Sarepta from the offering are expected to be approximately $575 million.

Baird served as co-manager on this offering.

About

Sarepta is on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. Sarepta holds leadership positions in Duchenne muscular dystrophy (DMD) and limb-girdle muscular dystrophies (LGMDs), and the Company currently has more than 40 programs in various stages of development. Sarepta’s vast pipeline is driven by the Company’s multi-platform Precision Genetic Medicine Engine in gene therapy, RNA and gene editing. Sarepta Therapeutics, Inc. is headquartered in Cambridge, Massachusetts.

Healthcare

Sarepta follow-on offering